TGBA01AD

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
TGBA01AD
Clinical data
Routes of
administration		 Oral
Pharmacokinetic data
Bioavailability 17%[1]
Biological half-life 4 hours[2]

TGBA01AD is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[1] [2] As of May 2015, the Fabre-Kramer website lists TGBA01AD as being in phase II clinical trials.[2]

See also

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links



<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ 2.0 2.1 http://www.fabrekramer.com/?page_id=66
Retrieved from "https://infogalactic.com/w/index.php?title=TGBA01AD&oldid=713253297"